Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient

• US 5,855,908 A
• Filed: 11/15/1994
• Issued: 01/05/1999
• Est. Priority Date: 05/01/1984
• Status: Expired due to Term

• Current Assignee: University of Utah Research Foundation (State of Utah)
• Original Assignee: University of Utah Research Foundation (State of Utah)
• Inventors: Hague, Brian, Stanley, Theodore H.
• Primary Examiner(s): Bawa, Raj
• Application Number:
  US08/339,655
• Time in Patent Office: 1,512 Days
• Field of Search: 424/440, 424/441, 424/439, 514/948
• US Class Current: 424/440
• CPC Class Codes: A23G 3/368 containing vitamins, antibiotics
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Abstract

Compositions and methods of manufacture for producing a medicament composition capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus. The present invention relates to such compositions and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner such that sufficient drug is administered to produce precisely a desired effect. The invention also relates to manufacturing techniques that enable therapeutic agents to be incorporated into nondissolvable drug containment matrixes which are capable of releasing the drug within a patient'"'"'s mouth. An appliance or holder is preferably attached to the drug containment matrix. Employing the present invention the drug may be introduced into the patient'"'"'s bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the negative aspects of both of these methods. The nondissolvable drug containment matrix may include permeation enhancers to increase the drug absorption by the mucosal tissues of the mouth. The matrix composition may also include pH buffering agents to modify the salival pH thereby increasing the absorption of the drug through the mucosal tissues.

Claims

1. A drug-containing dosage-form for use in the transmucosal delivery of a drug to a patient, the dosage-form consisting essentially of:

(a) a drug containment matrix which is nondissolvable by the saliva in the mouth of the patient and which is designed to be nonfrangible in the mouth of the patient, the drug containment matrix containing a pharmacologically effective dose of a drug so that the nondissolvable drug containment matrix is capable of being sucked on or passively held within the mouth and is configured to release the drug within the mouth of the patient for adsorption through mucosal tissues of the mouth, pharynx, and esophagus, the drug containment matrix also having a holder means secured thereto, the holder means being configured to permit convenient insertion and removal of the drug containment matrix into and out of the mouth of the patient in a dose-to-effect manner; and

(b) a buffer including citric acid/sodium citrate held within the drug containment matrix.

2. A drug-containing dosage-form as recited in claim 1, wherein the buffer further includes a phosphate buffer system.

3. A drug-containing dosage-form as recited in claim 1, wherein the buffer is incorporated in an amount of about 1% by weight.

4. A drug-containing dosage-form for use in the transmucosal delivery of a drug to a patient, the dosage-form consisting essentially of:

(a) a drug containment matrix which is nondissolvable by the saliva in the mouth of the patient and which is designed to be nonfrangible in the mouth of the patient, the drug containment matrix containing a pharmacologically effective dose of a drug so that the nondissolvable drug containment matrix is capable of being sucked on or passively held within the mouth and is configured to release the drug within the mouth of the patient for adsorption through mucosal tissues of the mouth, pharynx, and esophagus, the drug containment matrix also having a holder means secured thereto, the holder means being configured to permit convenient insertion and removal of the drug containment matrix into and out of the mouth of the patient in a dose-to-effect manner; and

(b) a buffer including a phosphate buffer system held within the drug containment matrix.

5. A drug-containing dosage-form as recited in claim 4, wherein the buffer is incorporated in an amount of about 1% by weight.